Flortaucipir F 18 Pregnancy and Breastfeeding Warnings

Brand names: Tauvid

Flortaucipir F 18 Pregnancy Warnings

Use is not recommended.

US FDA pregnancy category: Not assigned

Risk summary:
All radiopharmaceuticals, including this drug, have the potential to cause fetal harm, and the extent of the harm may depend on the stage of fetal development and the level of radiation exposure.

Comments:
-It is important to inform a pregnant woman about the possible risks associated with administering this drug, as it may result in radiation exposure to the fetus.
-This drug is unlikely to be administered to women who are of reproductive age.

There have been no studies on animal reproduction that have investigated the impact of this drug on the development of female reproduction or embryo-fetal growth. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Flortaucipir F 18 Breastfeeding Warnings

Breastfeeding is not recommended for 4 hours after administration of this drug.

Excreted into human milk: Data not available
Excreted into animal milk: Data not available

Comments:
-The effects in the nursing infant or milk production are unknown.
-Lactation studies have not been conducted in animals.
-To reduce radiation exposure to a breastfed infant, it is recommended that a lactating woman refrain from breastfeeding for four hours after administration of this drug.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer